- NCIt
- C7480
Loading cancer entity…
Loading cancer entity…
Clinical trials
744 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (121)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00003382 | Combination Chemotherapy Consisting of Gemcitabine And Topotecan in Treating Patients With Refractory or Recurrent Ovarian or Fallopian Tube Cancer | terminated | Phase 1 | — | Gynecologic Oncology GroupNETWORK | 1 | Jun 10, 2013 | clinicaltrials |
| NCT00369954 | Gemcitabine and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer That Responded to Previous Cisplatin or Carboplatin | withdrawn | Phase 2 | 0 | Gynecologic Oncology GroupNETWORK | 0 |
| Jun 10, 2013 |
| clinicaltrials |
| NCT00058435 | Monoclonal Antibody Vaccine Therapy in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer | completed | Phase 1 | — | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 5, 2013 | clinicaltrials |
| NCT00017017 | CT-2103 in Treating Patients With Recurrent Ovarian Epithelial or Fallopian Tube Cancer or Primary Peritoneal Cancer | completed | Phase 1 / Phase 2 | — | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 30, 2013 | clinicaltrials |
| NCT00003385 | Combination Chemotherapy in Treating Patients With Untreated Ovarian, Peritoneal, or Fallopian Tube Cancer | completed | Phase 1 | 48 | Gynecologic Oncology GroupNETWORK | 2 | May 27, 2013 | clinicaltrials |
| NCT00003967 | Topotecan Plus Etoposide in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer | completed | Phase 1 | 24 | Gynecologic Oncology GroupNETWORK | 1 | May 27, 2013 | clinicaltrials |
| NCT01851928 | Validation of a Nutrition Screening Tool | completed | — | 128 | Royal Marsden NHS Foundation TrustOTHER | 1 | May 13, 2013 | clinicaltrials |
| NCT00003944 | Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 2 | 3 | Fox Chase Cancer CenterOTHER | 1 | Apr 17, 2013 | clinicaltrials |
| NCT00003624 | Amifostine in Treating Women With Ovarian, Peritoneal, Cervical, Fallopian Tube, Uterine, or Endometrial Cancer | terminated | Phase 2 | — | Gynecologic Oncology GroupNETWORK | 1 | Apr 11, 2013 | clinicaltrials |
| NCT00842452 | Topotecan in Treating Patients With Gynecologic Cancer That Cannot Be Removed by Surgery | completed | Phase 1 | 26 | Steven Waggoner, MDOTHER | 1 | Apr 5, 2013 | clinicaltrials |
| NCT00004074 | Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu | completed | Phase 1 | 15 | National Cancer Institute (NCI)NIH | 1 | Feb 28, 2013 | clinicaltrials |
| NCT00004934 | Paclitaxel and Carboplatin With or Without Epirubicin in Treating Patients With Stage IIB, Stage III, or Stage IV Invasive Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer | completed | Phase 3 | — | Nordic Society of Gynaecological Oncology - Clinical Trials UnitOTHER | 10 | Feb 4, 2013 | clinicaltrials |
| NCT00003358 | Cisplatin and Gemcitabine in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 1 | 24 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00087191 | EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer | terminated | N/A | 30 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00003896 | S9912 Combination Chemo in Stage III Ovarian Cancer, | completed | Phase 2 | 68 | SWOG Cancer Research NetworkNETWORK | 1 | Jan 4, 2013 | clinicaltrials |
| NCT00672295 | PH I SRC Kinase, Dasatinib Combo Paclitaxel & Carboplatin in Pts w Ovarian, Peritoneal, & Tubal Cancer | completed | Phase 1 | 11 | AA SecordOTHER | 1 | Dec 28, 2012 | clinicaltrials |
| NCT00288275 | Correlation of the Chemoresponse Assay With PFS in Patients With Recurrent Epithelial Ovarian, Peritoneal, or Fallopian Tube Cancer | terminated | — | 256 | Precision TherapeuticsINDUSTRY | 1 | Oct 5, 2012 | clinicaltrials |
| NCT00669422 | ChemoFx® PRO - A Post-Market Data Collection Study | terminated | — | 2,756 | Precision TherapeuticsINDUSTRY | 1 | Oct 5, 2012 | clinicaltrials |
| NCT01661868 | Olaparib for Patients With Recurrent BRCA Deficient Ovarian Cancer | withdrawn | Phase 2 | 0 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 21, 2012 | clinicaltrials |
| NCT00501644 | Chemoimmunotherapy Study for Patients With Epithelial Ovarian Cancer | completed | Phase 2 | 59 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 7, 2012 | clinicaltrials |
| NCT00059618 | PS-341 Plus Carboplatin in Platinum and Taxane Resistant Recurrent Ovarian Cancer, Primary Peritoneal Cancer, and Fallopian Tube Cancer | completed | Phase 1 | 21 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 2, 2012 | clinicaltrials |
| NCT00085384 | PEG-Interferon Alfa-2b in Treating Patients With Platinum-Resistant Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer | terminated | Phase 1 / Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 2, 2012 | clinicaltrials |
| NCT00032162 | Liposomal Doxorubicin and Carboplatin in Treating Patients With Gynecologic Cancer | completed | Phase 1 / Phase 2 | 63 | AGO Study GroupOTHER | 1 | May 31, 2012 | clinicaltrials |
| NCT00653328 | Ph II Atrasentan + DOXIL in Recurrent Ovarian/Fallopian/Peritoneal Serous Papillary Adenocarcinoma | terminated | Phase 2 | 15 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | May 23, 2012 | clinicaltrials |
| NCT00004060 | Chemotherapy in Treating Patients With Recurrent, Metastatic, or Unresectable Ovarian, Fallopian Tube, or Peritoneal Cancer | completed | Phase 2 | — | Daiichi SankyoINDUSTRY | 1 | May 16, 2012 | clinicaltrials |
| NCT00505661 | Letrozole in Patients With Ovarian Tumors | terminated | Phase 2 | 16 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 18, 2012 | clinicaltrials |
| NCT01570582 | A Phase IIclinical Trial of Carboplatin and Paclitaxel or Carboplatin and Gemcitabine in Platinum-sensitive, Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer | unknown | Phase 2 | 314 | Korean Gynecologic Oncology GroupOTHER | 1 | Apr 4, 2012 | clinicaltrials |
| NCT01096381 | Potential Biomarkers for Bevacizumab-Induced High Blood Pressure in Patients With Solid Tumor | terminated | — | 8 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Feb 27, 2012 | clinicaltrials |
| NCT00245050 | Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Liposomal Doxorubicin for Cancer | completed | Phase 3 | 34 | Case Comprehensive Cancer CenterOTHER | 1 | Dec 30, 2011 | clinicaltrials |
| NCT00466986 | Abraxane Plus Carboplatin for Recurrent Platinum-Sensitive Ovarian Cancer | completed | Phase 2 | 40 | Southeastern Gynecologic OncologyOTHER | 1 | Oct 12, 2011 | clinicaltrials |
| NCT01048814 | Retrospective Case Study to Validate Existing Chemoresponse Marker Test in Ovarian, Peritoneal or Fallopian Cancer Cases | completed | — | 512 | Precision TherapeuticsINDUSTRY | 1 | Jun 3, 2011 | clinicaltrials |
| NCT00028912 | Bortezomib and Carboplatin in Treating Patients With Recurrent or Progressive Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | completed | Phase 1 | — | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 26, 2011 | clinicaltrials |
| NCT00003160 | Weekly Infusions of Paclitaxel in Treating Women With Stage III or Stage IV Ovarian Cancer Refractory to Paclitaxel and Platinum | unknown | Phase 2 | 100 | TheradexINDUSTRY | 1 | Apr 20, 2011 | clinicaltrials |
| NCT00006391 | Oxaliplatin and Topotecan in Treating Patients With Previously Treated Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | completed | Phase 1 | — | NYU Langone HealthOTHER | 1 | Apr 5, 2011 | clinicaltrials |
| NCT00189566 | Taxol® in Monotherapy or in Combination With Topotecan or Carboplatin in Patients With Epithelial Ovarian Cancer in Early Relapse | completed | Phase 2 | 165 | ARCAGY/ GINECO GROUPOTHER | 1 | Feb 25, 2011 | clinicaltrials |
| NCT00517621 | Use of FACT-GOG/NTX Questionnaire in Peripheral Neurotoxicity & Validation of a French Version of This Questionnaire | completed | Phase 2 | 100 | ARCAGY/ GINECO GROUPOTHER | 1 | Feb 25, 2011 | clinicaltrials |
| NCT00217529 | Erlotinib, Docetaxel, and Carboplatin in Treating Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer | completed | Phase 1 / Phase 2 | — | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 21, 2010 | clinicaltrials |
| NCT00217555 | Gemcitabine and Topotecan in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer | completed | Phase 2 | — | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 21, 2010 | clinicaltrials |
| NCT01074398 | Biomarkers in Predicting Response in Patients With Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Treated on GOG-0172 or GOG-0182 | unknown | — | 513 | Gynecologic Oncology GroupNETWORK | 0 | Feb 24, 2010 | clinicaltrials |
| NCT00238342 | Proteomic Profiling in Diagnosing Ovarian Cancer in Patients Who Are Undergoing Surgery for an Abnormal Pelvic Mass | unknown | N/A | 2,000 | Gynecologic Oncology GroupNETWORK | 1 | Feb 9, 2010 | clinicaltrials |
| NCT00905658 | Nutritional Supplements in Improving Quality of Life During First-Line Chemotherapy in Patients With Metastatic Gynecological Cancer | unknown | Phase 2 | 120 | Centre Oscar LambretOTHER | 1 | Jul 29, 2009 | clinicaltrials |
| NCT00753480 | A Study of D4064A Administered to Patients With Recurrent or Persistent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | suspended | Phase 1 | 56 | Genentech, Inc.INDUSTRY | 1 | Nov 7, 2008 | clinicaltrials |
| NCT00157560 | Phase II Study of Modified Triple Doublet Therapy in Women With Newly Diagnosed Mullerian Carcinoma | completed | Phase 2 | 83 | Massachusetts General HospitalOTHER | 1 | Jan 3, 2008 | clinicaltrials |
Data updated 22 days agoSource updated Jun 10, 2013source: clinicaltrials